Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV).
Company facts
| Company | Arbutus Biopharma Corporation |
|---|---|
| Symbol | ABUS |
| Exchange | XNAS |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.01B (Massive market data, 2026-09-10) |
| Employees | 19 |
| Country | United States |
| Website | https://www.arbutusbio.com |
Trading — Arbutus Biopharma Corporation
| Last price | $5.12 |
|---|---|
| Change | 0.00% |
| Previous close | $5.12 |
| Day range | $5.11 – $5.18 |
| 50-day average | $4.79 |
| 200-day average | $4.51 |
| Average volume | 1,965,205 |
Price basis: yfinance_daily_bar_close · 2026-09-11T21:07:44.986755+00:00
Valuation and financial health
| Earnings per share | $0.77 |
|---|---|
| Price / book | 3.92 |
| Enterprise value / EBITDA | 6.68 |
| Enterprise value / sales | 5.49 |
| Debt / equity | 0.01 |
| Current ratio | 81.42 |
| Dividend yield | 0.00% |
| Free cash flow | -$24.62M |
| Cash ratio | 5.70 |
| Enterprise value | $998.24M |
Reported 2026-09-10
Earnings
| Report date | 2026-11-16 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | 2026-09-30 |
| EPS estimate | -0.0232 |
Source: optionsai supplemental public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for ABUS are on the IntelTrends dashboard.